Loading
Life sciences · Journal article
Experimental and Theoretical Nanotechnology · October 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The incidence and mortality of cancer have increased worldwide. The limitations of available anticancer agents in reducing mortality have encouraged researchers to develop an alternative therapy. Recently, green - synthesized nanoparticles have emerged as promising potential alternative therapeutic strategies. This study focused on the anticancer activities of gold nanoparticles (AuNPs) against two types of cancer cells: human breast cancer cell line (MDA-MB-231) and human prostate cancer (PC3), with a particular focus on the expression of the tumor suppressor genes p53 and p21. Green synthesis of AuNPs from Ziziphus spina-christi (Z. spina-christi) is carried out, followed by morphological and physical characterization. Their anticancer activity against the human breast cancer cell line (MDA-MB-231) and human prostate cancer (PC3) is evaluated, along with their effect on the expression of tumor suppressor genes p53 and p21. The prepared AuNPs showed significant anticancer and cytotoxic activities against both cancer cell lines. The sensitivity of the PC3 cell line is higher than that of the MDA-MB-231 cell line when the percentages of viability are 48.74%, 33.47%, and 23.15% at 200, 400, and 800 µg/ ml, respectively. 5.43- and 6.41-fold increases in the expression of the p53 and p21 genes, respectively, are observed in the PC3 cell line when treated with AuNPs, compared to untreated cells.